Form Approved OMB No. 0923-0041 Exp. Date xx/xx/201x

National Amyotrophic Lateral Sclerosis (ALS) Registry Research Application Form:

Type of request Research notification Data Biospecimens or tissues (mark all that apply) Before submitting your application, please attach a copy of the following required materials in the web form on the application page. All materials received by the Agency for Toxic Substances and Disease Registry (ATSDR) have to be in pdf format. • Research Application Form. • Cover letter with a brief overview of the project, highlighting the importance of the research proposal. • PI CV or Biosketch. • Full study protocol, including consent form if applicable. • Confirmation of IRB approval of full protocol and informational materials. • Additional supporting documents. • For clinical notifications include the recruitment letter and/or informational materials to be sent to potential study participants and complete Part A. • For specimens include completed specimen request form(s) (Part B and/or Part C) including types and number of specimens requested. Date (mm/dd/yyyy): Title of Study or Project: Principal Investigator (or Project Director): Short_Title: Organization: Co-Principal Investigator (if any): (if there are no Co-Pl's enter "None.")
the application page. All materials received by the Agency for Toxic Substances and Disease Registry (ATSDR) have to be in pdf format. Research Application Form. Cover letter with a brief overview of the project, highlighting the importance of the research proposal. PI CV or Biosketch. Full study protocol, including consent form if applicable. Confirmation of IRB approval of full protocol and informational materials. Additional supporting documents. For clinical notifications include the recruitment letter and/or informational materials to be sent to potential study participants and complete Part A. For specimens include completed specimen request form(s) (Part B and/or Part C) including types and number of specimens requested. Date (mm/dd/yyyy): Title of Study or Project: Principal Investigator (or Project Director): Short Title: Organization: Co-Principal Investigator (if any): (if there are no Co-PI's enter "None.")
 Cover letter with a brief overview of the project, highlighting the importance of the research proposal. PI CV or Biosketch. Full study protocol, including consent form if applicable. Confirmation of IRB approval of full protocol and informational materials. Additional supporting documents. For clinical notifications include the recruitment letter and/or informational materials to be sent to potential study participants and complete Part A. For specimens include completed specimen request form(s) (Part B and/or Part C) including types and number of specimens requested. Date (mm/dd/yyyy): Title of Study or Project: Principal Investigator (or Project Director): Short Title: Organization:
 Confirmation of IRB approval of full protocol and informational materials. Additional supporting documents. For clinical notifications include the recruitment letter and/or informational materials to be sent to potential study participants and complete Part A. For specimens include completed specimen request form(s) (Part B and/or Part C) including types and number of specimens requested. Date (mm/dd/yyyy): Title of Study or Project: Principal Investigator (or Project Director): Co-Principal Investigator (if any): (if there are no Co-Pl's enter "None.")
O For clinical notifications include the recruitment letter and/or informational materials to be sent to potential study participants and complete Part A. O For specimens include completed specimen request form(s) (Part B and/or Part C) including types and number of specimens requested. Date (mm/dd/yyyy): Title of Study or Project: Principal Investigator (or Project Director): Short Title: Organization: Co-Principal Investigator (if any): (if there are no Co-PI's enter "None.")
O For specimens include completed specimen request form(s) (Part B and/or Part C) including types and number of specimens requested. Date (mm/dd/yyyy): Title of Study or Project: Principal Investigator (or Project Director): Short Title: Organization: Co-Principal Investigator (if any): (if there are no Co-PI's enter "None.")
Title of Study or Project: Principal Investigator (or Project Director): Short Title: Co-Principal Investigator (if any): (if there are no Co-PI's enter "None.")
Principal Investigator (or Project Director): Short Title: Organization: Co-Principal Investigator (if any): (if there are no Co-PI's enter "None.")
Short <u>Title:</u> Co-Principal Investigator (if any): (if there are no Co-PI's enter "None.")
Co-Principal Investigator (if any): (if there are no Co-PI's enter "None.")
Name(s) Organization(s) Business Phone Number Business Email Address

CDC estimates the average public reporting burden for this collection of information as 30 minutes per response, including the time for reviewing instructions, searching existing data/information sources, gathering and maintaining the data/information needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC/ATSDR Information Collection Review Office, 1600 Clifton Road NE, MS D-74, Atlanta, Georgia 30333; ATTN: PRA (0923-0041).

Funding source and any declared (to the IRB) financial conflicts of interest:
<u>Funding source</u> : List the source(s) of funding for the project and this sample, the amount of funding anticipated from each source, and indicate the type of support provided: i.e., grant, contract, cooperative agreement, interagency agreement, other (specify), and note if the funding is current or is pending.
<u>Declared conflict of interest</u> : For each investigator please list any financial conflicts of interest declared to the IRB.
Summary of Proposed Study Protocol or Project Activities: Provide a brief summary of your proposed study or project activities. Provide sufficient detail to describe your study or project. If you are requesting data and/or biospecimens or tissues obtained from the National ALS Registry describe how they will be used. Include in this summary the ALS study population in which you are interested, describe the benefit of this study to the community or individuals involved, demonstrate an understanding of the scientific merit of your proposed study, include a description of the hypothesis to be tested and some background information to support why the study or project is being proposed, and include a brief description of your proposed methods and analytic plan. (The summary should be limited to 7000 characters.)
Background:
Specific Aims:
Methods:
Population:
Measures:

Analysis:
Institutional Review Board (IRB) for the Protection of Human Subjects:
(As defined by the U.S. Department of Health and Human Services in the Code of Federal Regulations, Title 45, Part 46): Evidence of a current IRB approval is required prior to the ATSDR contacting ALS registrants.
Please provide the following information on the IRB to review this project outside of ATSDR:
Name and address of the IRB:
IRB Federal Wide Assurance (FWA) number:
Does this study have current approval from this IRB?
If Yes, Date of the IRB approval (mm/dd/yyyy):
Please provide a lay summary of not more than 250 words that describes the purpose of your research, what

Please provide a lay summary of not more than 250 words that describes the purpose of your research, what information you hope to obtain, who can participate, number of participants, and what participants must do to take part including time commitment. Remember the average high school graduate reads at the 8th grade level so use simple declarative sentences and avoid scientific jargon.

Part A - Research Notification

Will any of the information (obtained from the National ALS Registry, or from the request for ATSDR to inform ALS registrants about the proposed study) be used as a basis for legal, administrative, or other actions which may directly affect particular individuals or establishments as a result of their specific identification in this project?
Yes No Maybe
If Yes or Maybe, please explain:
Will any of the information (obtained from the National ALS Registry, or from the request for ATSDR to inform ALS registrants about the proposed study) be used as a basis for marketing purposes, including, but not limited to, marketing of pharmaceutical drugs?
Yes No Maybe
If Yes or Maybe, please explain:
The following variables are available for all registrants and can be used to prescreen registrants for notification about your study. Please indicate which variables you would like us to use and specific criteria.
Specific Age Range at Diagnosis (e.g. 40-50, 50-60, 60-75):
Specific year/years of diagnosis (e.g. 2012 - current):
Specific Sex (e.g. female only, male only):
City and / or State(s) of residence or region of the United States (e.g. Los Angeles, CA, Dallas, TX, State of Arizona, State of Georgia and Florida):
*Additional variables are available on a subset of the population, such as registrants with a history of military service, smoking / alcohol consumption or specific ALSFRS score. If you wish to use these as eligibility requirements, please contact the ALS Research Notification System Administrator.
I do not want to prescreen for eligibility (e.g. I want to have research materials sent to all participants taking part in the notification process.).

* Recount ests to have ATSDR identify additional variables for eligible participant(s) may delay the distribution of research materials. If you have questions or concerns about the application process or status of your application, please contact the ALS Research Notification System Administrator at 877-442-9719 (Monday through Friday, 9am to 5pm ET). You may also send us an email at ALSResearch@cdc.gov.

ATSDR kindly requests that researchers include the following acknowledgement in any publications deriving from the study:

"Recruitment for this study was in part made possible by ATSDR's National ALS Registry Research Notification Mechanism (http://wwwn.cdc.gov/ALS/ALSClinicalResearch.aspx)" and that they forward such publications to ATSDR (ALSResearch@cdc.gov).

Part B- National ALS Biorepository

Date of Request:	

			MPLES		
SAMPLE TYPE	ALIQ UOT SIZE	PRICE/ ALIQUOT	NUMBER OF INDIVIDUA LS REQUESTE D	REQUESTE D NUMBER OF ALIQUOTS/I NDIVIDUAL	TOTAL ALIQUO TS
PLASMA	0.5				
BUFFY COAT RED BLOOD	1.0 ml				
CELL WHOLE BLOOD	1.8 ml				
(metals free)					
SERUM	0.5 ml				
RNA	2 ug				
DNA	2 ug				
URINE	1 ml				
URINE (Hg preservati ve)	1 ml				
HAIR NAILS					

SURVEY DATA

Comments/Special Instructions:	

CONTACT INFORMATION

*All speemen requests include demographics when	
available, including: age at diagnosis; age at first	Protocol #
symptom; age at death; race; sex; family history of ALS;	
family history of other NGD; state of residence; ALSFRS	Title of Study or Project
closest to collection; and survival time.	The or stacy of 110 ject
	Principal Investigator or Project Director_
Are you interested in additional Survey Data? Note,	Timelput investigator of Project Director_
not all survey data may be available at this time.	Organization_
Yes No	Organization_
If yes, please select from the options below:	Contact Phone Number
Demographics	Contact Finance Fulliper
Occupational History	Email Address
Military History	Email Address
Smoland/Alcohol History	
Smoking/Alcohol History	SHIPPING INFORMATION
Physical Activity	SHIPPING INFORMATION LAB CONTACT:
Physical Activity Disease Progression (ALSFRS)	SHIPPING INFORMATION LAB CONTACT:
Physical Activity Disease Progression (ALSFRS) Family History of Neurological Diseases	LAB CONTACT:
Physical Activity Disease Progression (ALSFRS) Family History of Neurological Diseases Clinical Data (e.g. devices used, body onset)	
Physical Activity Disease Progression (ALSFRS) Family History of Neurological Diseases Clinical Data (e.g. devices used, body onset) Lifetime Residential History	LAB CONTACT: LAB TELEPHONE:
Physical Activity Disease Progression (ALSFRS) Family History of Neurological Diseases Clinical Data (e.g. devices used, body onset) Lifetime Residential History Lifetime Occupational History	LAB CONTACT:
Physical Activity Disease Progression (ALSFRS) Family History of Neurological Diseases Clinical Data (e.g. devices used, body onset) Lifetime Residential History Lifetime Occupational History Residential Pesticide Use	LAB CONTACT: LAB TELEPHONE:
Physical Activity Disease Progression (ALSFRS) Family History of Neurological Diseases Clinical Data (e.g. devices used, body onset) Lifetime Residential History Lifetime Occupational History Residential Pesticide Use Hobbies with Toxicant Exposures	LAB CONTACT: LAB TELEPHONE:
Physical Activity Disease Progression (ALSFRS) Family History of Neurological Diseases Clinical Data (e.g. devices used, body onset) Lifetime Residential History Lifetime Occupational History Residential Pesticide Use Hobbies with Toxicant Exposures Caffeine Consumption	LAB CONTACT: LAB TELEPHONE: LAB CONTACT EMAIL:
Physical Activity Disease Progression (ALSFRS) Family History of Neurological Diseases Clinical Data (e.g. devices used, body onset) Lifetime Residential History Lifetime Occupational History Residential Pesticide Use Hobbies with Toxicant Exposures Caffeine Consumption Reproductive History (women)	LAB CONTACT: LAB TELEPHONE: LAB CONTACT EMAIL:
Physical Activity Disease Progression (ALSFRS) Family History of Neurological Diseases Clinical Data (e.g. devices used, body onset) Lifetime Residential History Lifetime Occupational History Residential Pesticide Use Hobbies with Toxicant Exposures Caffeine Consumption Reproductive History (women) Health Insurance Status	LAB CONTACT: LAB TELEPHONE: LAB CONTACT EMAIL:
Physical Activity Disease Progression (ALSFRS) Family History of Neurological Diseases Clinical Data (e.g. devices used, body onset) Lifetime Residential History Lifetime Occupational History Residential Pesticide Use Hobbies with Toxicant Exposures Caffeine Consumption Reproductive History (women)	LAB CONTACT: LAB TELEPHONE: LAB CONTACT EMAIL:

Part C- National ALS Biorepository Postmortem Sample Request Form

Date of Request:

		SAMPLES		
SAMPLE TYPE	PRICE/SAMPLE	NUMBER OF INDIVIDUALS REQUESTED	REQUESTED NUMBER OF SAMPLE/INDIVIDUAL	TOTAL SAMPLE
Frozen tissue (0.5-1g)				
Precentral motor cortex	\$80			
Cervical spinal cord	\$100			
Thoracic spinal cord	\$100			
Lumbar spinal cord	\$100			
Other:				
Parafin-embedded fixed tissue sections (5 sections at 5um)				

Olfactory bulb	\$60		
Midbrain at level of red nucleus	\$60		
Midbrain at decussation of the superior cerebellar peduncle	\$60		
Precentral motor and postcentral sensory cortex (Brodmann area (BA) 4, 3, 2, 1)	\$40		
Precentral motor cortex	\$40		
Inferior parietal cortex (BA 39,40)	\$40		
Anterior cingulate (BA 24)	\$40		
Superior frontal (BA 8)	\$40		
Inferior frontal cortex (BA 10,11,12)	\$40		
Middle frontal cortex (BA 8,9) at level of CAP	\$40		
Caudate nucleus, putamen, and nucleus accumbens (CAP)	\$40		
Anterior temporal (BA 38)	\$40		
Superior temporal (BA 20, 21,22)	\$40		
Amygdala, with entorhinal cortex (BA 28)	\$60		
Globus pallidus, putamen with claustrum, insula and substantia innominata	\$60		
Anterior hippocampus	\$60		
Hippocampal formation at level of lateral geniculate body, tail of caudate	\$60		
Superior temporal posterior (BA 41,42)	\$40		
Thalamus with centromedian, dorsal medial, lateral dorsal and lateral posterior nuclei	\$60		
Thalamus with subthalamic nucleus, mammillary body	\$60		
Posterior cingulate (BA23, 31)	\$40		
Calcarine cortex (BA 17,18)	\$40		
Superior parietal cortex (BA 7b)	\$40		
Upper pons (level of locus cœruleus)	\$60		
Lower pons at Vth cranial nerve	\$60		
Medulla oblongata (including inferior olives)	\$60		
Cervical spinal cord	\$60		
Thoracic spinal cord	\$60		
		-	

_	₹				
	Lumbar spinal cord	\$60			
Sacr	al spinal cord	\$60			
Cere	bellar vermis	\$60			
Cere	bellum with dentate nucleus	\$60			
BA 1	9	\$40			
Con	nments/Special Instructions:			!	
	SURVEY DATA		CONTACT INI	FORMATION	
	specimen requests include demo	graphics when		FORMATION	
avai	specimen requests include demo lable, including: age at diagnosis;	graphics when age at first	CONTACT INI Protocol #	FORMATION	
avai sym fam	specimen requests include demo lable, including: age at diagnosis; ptom; age at death; race; sex; fam ly history of other NGD; state of	graphics when age at first hily history of ALS; residence; ALSFRS			
avai sym fam clos	specimen requests include demo lable, including: age at diagnosis; ptom; age at death; race; sex; fam ly history of other NGD; state of est to collection; and survival tim	graphics when age at first hily history of ALS; residence; ALSFRS e.	Protocol # Title of Study or Pro	oject	
avai sym fam clos	specimen requests include demo lable, including: age at diagnosis; ptom; age at death; race; sex; famly history of other NGD; state of est to collection; and survival tim	graphics when age at first hily history of ALS; residence; ALSFRS e.	Protocol # Title of Study or Pro		
avai sym fam clos	specimen requests include demo lable, including: age at diagnosis; ptom; age at death; race; sex; fam ly history of other NGD; state of est to collection; and survival tim	graphics when age at first hily history of ALS; residence; ALSFRS e.	Protocol # Title of Study or Pro	oject	
avai sym fam clos Are	specimen requests include demo lable, including: age at diagnosis; ptom; age at death; race; sex; family history of other NGD; state of est to collection; and survival times you interested in additional Surall survey data may be available and Yes No	graphics when age at first hily history of ALS; residence; ALSFRS e. rvey Data? Note, at this time.	Protocol # Title of Study or Pro	oject or or Project Director_	
avai sym fam clos Are	specimen requests include demo lable, including: age at diagnosis; ptom; age at death; race; sex; fam ly history of other NGD; state of est to collection; and survival tim you interested in additional Su all survey data may be available a	graphics when age at first hily history of ALS; residence; ALSFRS e. rvey Data? Note, at this time.	Protocol # Title of Study or Protocol # Principal Investigate Organization_	oject or or Project Director_	

Occupational History	
Military History	SHIPPING INFORMATION
Smoking/Alcohol History	LAB CONTACT:
Physical Activity	
Disease Progression (ALSFRS)	LAB TELEPHONE:
Family History of Neurological Diseases	ELD TELLITORE.
Clinical Data (e.g. devices used, body onset)	LAR CONTACT THAT
Lifetime Residential History	LAB CONTACT EMAIL:
Lifetime Occupational History	
Residential Pesticide Use	LAB SHIPPING ADDRESS:
Hobbies with Toxicant Exposures	
Caffeine Consumption	
Reproductive History (women)	
Health Insurance Status	
Trauma History	

Part D – National ALS Registry Data only request

The National ALS Registry collects a variety of risk factor data.

Please select from the options below (mark all that apply): Note that not all survey data may be available at this time.

Demographics	
Occupational History	
Military History	
Smoking/Alcohol History	
Physical Activity	
Disease Progression (ALSFRS)	
Family History of Neurological Diseases	
Clinical Data (e.g. devices used, body onset)	
Lifetime Residential History	
Lifetime Occupational History	
Residential Pesticide Use	
Hobbies with Toxicant Exposures	
Caffeine Consumption	
Reproductive History (women)	
Health Insurance Status	
Trauma History	